Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
about
Unmet Needs in LDL-C Lowering: When Statins Won't Do!CETP Inhibition: Past Failures and Future HopesCurrent therapies for lowering lipoprotein (a)Zebrafish Models for Dyslipidemia and Atherosclerosis ResearchNew Era of Lipid-Lowering DrugsAntisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humansCholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.The controversy over the use of cholesteryl ester transfer protein inhibitors: is there some light at the end of the tunnel?CETP Inhibition in CVD Prevention: an Actual Appraisal.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.New directions for pharmacotherapy in the treatment of acute coronary syndrome.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Statin combination therapy and cardiovascular risk reduction.Hyperlipoproteinaemia(a) - apheresis and emerging therapies.Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Pharmacological management of diabetic dyslipidemia.Automation of PRM-dependent D3-Leu tracer enrichment in HDL to study the metabolism of apoA-I, LCAT and other apolipoproteins.Investigational therapies for hypercholesterolemia.Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.Lipoprotein(a): A missing culprit in the management of athero-thrombosis?Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?PCSK9 signaling pathways and their potential importance in clinical practice.The effect and safety of anacetrapib in the treatment of dyslipidemia: a systematic review and meta-analysis.Design, Synthesis, and Biological Evaluation of N,N-Disubstituted-4-Arylthiazole-2-Methylamine Derivatives as Cholesteryl Ester Transfer Inhibitors.Trials and Tribulations of CETP Inhibitors.Design, Synthesis and Biological Evaluation of N,N-Substituted Amine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors.Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?Novel treatment options for the management of heterozygous familial hypercholesterolemia.The role of lipoprotein (a) in chronic kidney disease.
P2860
Q26741705-A32FBD90-5481-4F7B-9C56-F13B2577BDDEQ26753158-E7B2BB99-01F5-4DBE-B229-C62CDE2D71D0Q26830297-1A0322FC-D752-4522-923B-33533705C87DQ28069803-8AD4749D-6A98-4308-B61F-EDAA9BB7CF34Q28072298-5901A8B1-502E-45AF-87E0-D52E7EDAC55DQ36617508-8156A978-9A17-4369-8342-7D3CC3CB5661Q37013499-F86B01A8-1E41-4156-ACD5-9BA7944FE078Q37150845-2785CA84-121F-41E5-A409-AD30C8C41324Q38589286-BE317EDF-7E22-41B3-8F14-6B12086CABBDQ38631018-14C2E090-CD71-46BF-A7A0-93E4BC4DC5CBQ38653210-ADED3D2F-2BE5-4007-A2FC-E5794B3DAEAEQ38707328-E68BD0AA-9AB0-481E-AB51-E7AD0CF3CE19Q38727796-DD387F4E-4B30-4EA2-B206-921782491C2FQ38780552-23019706-F14D-4548-B16E-112E1959D613Q38784639-C3DC3712-3F48-41B7-8857-40219EA7504EQ38786058-32C4293B-8D14-4484-8134-63BFBC133278Q38817144-61964ACC-12AD-4ACF-8852-CC64C758EF9EQ38832774-E1AD96D8-7AA1-457A-A4FB-69B2C650ABBFQ38839105-BE0AD693-2CFF-45B6-B0C8-C3197FDC3CFAQ38842531-59B4581B-5A8F-4E33-AAD6-2227D90180F4Q38881156-CBB72B19-E721-41F6-894E-03E755F6F38FQ38968510-0239E3DD-E616-4BC0-A8D0-B6A22544DEDCQ38985774-DB29360F-08AF-4C14-8192-ED7F5440FF0BQ39015072-7A313C73-7EA2-434C-8177-0A1FA72B21E6Q39174515-9517C707-2C0F-4152-A699-FE908A714B28Q39215123-FE655ED6-9AE1-46AA-9D80-A302A8FFD5BCQ39215606-787A2BE0-65E9-4CC3-B237-FACFD47E9AA0Q39368804-C24DC766-F1AF-4E1C-B179-307ED8277A08Q40068181-6FB6CF04-EFB0-4F8F-AA13-CD8F89002CFEQ43204658-84B912E7-099A-4B14-9357-868B521294C5Q47134612-F92C4B52-76FF-4870-BAAA-19527D3CB7ECQ47405486-993A7F61-96A9-4399-93C5-8125E3FCF969Q47431168-00FA78EC-33D7-4516-B261-00D417DEB8A2Q47669381-AD220DF0-B07B-4B6C-BC39-5FCDC6169773Q47708252-083C5BBA-E749-442C-B315-2E220196B906Q47726362-2AA70FFA-FE23-4063-9822-9E6E0CC49728Q47836175-5273611D-5398-483D-99CF-2DE1448E9EE4Q49598174-5AD8784E-8BBB-4327-8E50-C9E760433417
P2860
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@ast
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@en
type
label
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@ast
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@en
prefLabel
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@ast
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@en
P2093
P921
P3181
P1433
P1476
Cholesterol ester transfer pro ...... acebo-controlled phase 2 trial
@en
P2093
Daniel J Rader
G Kees Hovingh
H Bryan Brewer
John J P Kastelein
Patrick Round
Philip J Barter
Sander J H van Deventer
P304
P3181
P356
10.1016/S0140-6736(15)60158-1
P407
P577
2015-08-01T00:00:00Z